Radiotherapy and hepatocellular carcinoma: Update and review of the literature

S. Ursino, C. Greco, F. Cartei, C. Colosimo, A. Stefanelli, B. Cacopardo, M. Berretta, F. Fiorica

Research output: Contribution to journalArticle

Abstract

Historically radiotherapy has always played a limited role for the treatment of HCC due to the low tolerance of the liver and the subsequent risk of radiation induced liver disease (RILD). Technologist advancements in radiation planning and treatment delivery such as Stereotactic Body Radiotherapy (SBRT) combined with Image Guided Radiotherapy (IGRT) has allowed us to further increase tumor dose while maximally sparing the surrounding not involved liver. Furthermore, together with the growing knowledge of radiobiological models in liver disease, several mono-institutional retrospective and prosepective series are reporting very encouraging results. Therefore, radiotherapy might play a significant role for the treatment of unresectable HCC, alone or combined with other locoregional treatment such as transarterial chemoembolisation (TACE). The rationale for studying this technique is really strong and it should be tested in well designed prospective randomized clinical trials.

Original languageEnglish
Pages (from-to)1599-1604
Number of pages6
JournalEuropean Review for Medical and Pharmacological Sciences
Volume16
Issue number11
Publication statusPublished - 2012

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Liver Diseases
Image-Guided Radiotherapy
Radiation
Radiosurgery
Liver
Therapeutics
Randomized Controlled Trials
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • Liver radiotherapy
  • Stereotactic body radiotherapy
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Ursino, S., Greco, C., Cartei, F., Colosimo, C., Stefanelli, A., Cacopardo, B., ... Fiorica, F. (2012). Radiotherapy and hepatocellular carcinoma: Update and review of the literature. European Review for Medical and Pharmacological Sciences, 16(11), 1599-1604.

Radiotherapy and hepatocellular carcinoma : Update and review of the literature. / Ursino, S.; Greco, C.; Cartei, F.; Colosimo, C.; Stefanelli, A.; Cacopardo, B.; Berretta, M.; Fiorica, F.

In: European Review for Medical and Pharmacological Sciences, Vol. 16, No. 11, 2012, p. 1599-1604.

Research output: Contribution to journalArticle

Ursino, S, Greco, C, Cartei, F, Colosimo, C, Stefanelli, A, Cacopardo, B, Berretta, M & Fiorica, F 2012, 'Radiotherapy and hepatocellular carcinoma: Update and review of the literature', European Review for Medical and Pharmacological Sciences, vol. 16, no. 11, pp. 1599-1604.
Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B et al. Radiotherapy and hepatocellular carcinoma: Update and review of the literature. European Review for Medical and Pharmacological Sciences. 2012;16(11):1599-1604.
Ursino, S. ; Greco, C. ; Cartei, F. ; Colosimo, C. ; Stefanelli, A. ; Cacopardo, B. ; Berretta, M. ; Fiorica, F. / Radiotherapy and hepatocellular carcinoma : Update and review of the literature. In: European Review for Medical and Pharmacological Sciences. 2012 ; Vol. 16, No. 11. pp. 1599-1604.
@article{43872dc33bf741f1a791402d5827a348,
title = "Radiotherapy and hepatocellular carcinoma: Update and review of the literature",
abstract = "Historically radiotherapy has always played a limited role for the treatment of HCC due to the low tolerance of the liver and the subsequent risk of radiation induced liver disease (RILD). Technologist advancements in radiation planning and treatment delivery such as Stereotactic Body Radiotherapy (SBRT) combined with Image Guided Radiotherapy (IGRT) has allowed us to further increase tumor dose while maximally sparing the surrounding not involved liver. Furthermore, together with the growing knowledge of radiobiological models in liver disease, several mono-institutional retrospective and prosepective series are reporting very encouraging results. Therefore, radiotherapy might play a significant role for the treatment of unresectable HCC, alone or combined with other locoregional treatment such as transarterial chemoembolisation (TACE). The rationale for studying this technique is really strong and it should be tested in well designed prospective randomized clinical trials.",
keywords = "Hepatocellular carcinoma, Liver radiotherapy, Stereotactic body radiotherapy, Transarterial chemoembolization",
author = "S. Ursino and C. Greco and F. Cartei and C. Colosimo and A. Stefanelli and B. Cacopardo and M. Berretta and F. Fiorica",
year = "2012",
language = "English",
volume = "16",
pages = "1599--1604",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "11",

}

TY - JOUR

T1 - Radiotherapy and hepatocellular carcinoma

T2 - Update and review of the literature

AU - Ursino, S.

AU - Greco, C.

AU - Cartei, F.

AU - Colosimo, C.

AU - Stefanelli, A.

AU - Cacopardo, B.

AU - Berretta, M.

AU - Fiorica, F.

PY - 2012

Y1 - 2012

N2 - Historically radiotherapy has always played a limited role for the treatment of HCC due to the low tolerance of the liver and the subsequent risk of radiation induced liver disease (RILD). Technologist advancements in radiation planning and treatment delivery such as Stereotactic Body Radiotherapy (SBRT) combined with Image Guided Radiotherapy (IGRT) has allowed us to further increase tumor dose while maximally sparing the surrounding not involved liver. Furthermore, together with the growing knowledge of radiobiological models in liver disease, several mono-institutional retrospective and prosepective series are reporting very encouraging results. Therefore, radiotherapy might play a significant role for the treatment of unresectable HCC, alone or combined with other locoregional treatment such as transarterial chemoembolisation (TACE). The rationale for studying this technique is really strong and it should be tested in well designed prospective randomized clinical trials.

AB - Historically radiotherapy has always played a limited role for the treatment of HCC due to the low tolerance of the liver and the subsequent risk of radiation induced liver disease (RILD). Technologist advancements in radiation planning and treatment delivery such as Stereotactic Body Radiotherapy (SBRT) combined with Image Guided Radiotherapy (IGRT) has allowed us to further increase tumor dose while maximally sparing the surrounding not involved liver. Furthermore, together with the growing knowledge of radiobiological models in liver disease, several mono-institutional retrospective and prosepective series are reporting very encouraging results. Therefore, radiotherapy might play a significant role for the treatment of unresectable HCC, alone or combined with other locoregional treatment such as transarterial chemoembolisation (TACE). The rationale for studying this technique is really strong and it should be tested in well designed prospective randomized clinical trials.

KW - Hepatocellular carcinoma

KW - Liver radiotherapy

KW - Stereotactic body radiotherapy

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=84873458367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873458367&partnerID=8YFLogxK

M3 - Article

C2 - 23111978

AN - SCOPUS:84873458367

VL - 16

SP - 1599

EP - 1604

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 11

ER -